NEW YORK – Merck and Moderna announced Wednesday that a Phase III melanoma trial of Keytruda (pembrolizumab) and the personalized cancer vaccine intismeran autogene has met two key endpoints.
The firms will evaluate Ideaya's IDE892 with Genetech's GDC-7035 in MTAP-deleted, KRAS G12D-mutant pancreatic cancer.
The CAR T-cell therapy is the world's first approved for solid tumors and is being tested in a US-based trial.
The firm will use the proceeds to advance neuro-metabolic therapies, including a Phase I/II trial of an antisense oligonucleotide for ALS.
The firm reported $11.4 million in net revenue from Zevaskyn for the three months ended June 30, missing analysts' expectations of roughly $12.3 million.
The Chinese biotech said US regulators have cleared it to start trials of the therapy for patients with B-cell lymphoma.
PMC's new president and CEO said the organization is expanding beyond oncology, engaging with Capitol Hill, and challenging a controversial research grant rule.
NEW YORK – Akeso Bio has launched a Phase II study of a bispecific antibody-drug conjugate in combination with its bispecific antibody ivonescimab for advanced breast cancer. The Zhongshan, ...
The investigator-initiated trial comes after Elicio said a Phase II trial of ELI-002 7P in adjuvant pancreatic cancer did not meet its primary endpoint.
NEW YORK – Rocket Pharmaceuticals is discussing next steps to complete a pivotal Phase II trial of its Danon disease gene therapy, RP-A501, with the US Food and Drug Administration based on promising ...
US regulators are already reviewing data from a later-line trial, but Taiho now says it could seek a first-line indication for the EGFR inhibitor.
NEW YORK – The US Food and Drug Administration approved Laboratory Corporation of America's PGDx elio tissue complete as a companion diagnostic for detecting BRAF V600E and BRAF V600K mutations in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results